Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer
Cancer Chemotherapy and Pharmacology · 2024
DOI: 10.1007/s00280-024-04652-w ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Guangnan Zong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicin…. Hauptthemen laut MEDLINE: Antimetabolites, Antineoplastic, Capecitabine, Neoplasms, Therapeutic Equivalency. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Shandong New Times Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
Capecitabine (CAP) is one of the fluoropyrimidine deoxynucleoside carbamates, which can be converted to 5-fluorouracil (5-FU) by thymine deoxynucleoside phosphorylase (dThdPase) to exert antitumor effects. The purpose of this study is to compare the pharmacokinetics (PK), bioequivalence (BE), and safety of two CAP tablets in Chinese patients with solid tumor cancer. The results showed that the geometric mean ratios (GMRs) of Cmax, AUC0-t and AUC0-∞ of CAP T/R reagent were 90.26%, 95.27%, and 95.07, respectively. The values and 90% confidence intervals (CI) of AUC0-t, AUC0-∞, and Cmax all fall within the range of 80.00-125.00%. In addition, a total of 22 subjects in this study had 30 adverse events, with an incidence of 45.83%, and there were no serious adverse events and adverse events that led to withdrawal from the trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, No. 44 Wen Hua Xi Road, Jinan, 250012, People'…
- Shandong New Times Pharmaceutical Co., Ltd, Linyi, People's Republic of China.
- Clinical Trial Research Center, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of China.
ORCID-Profile: Xiuli Guo
Förderung
- Shandong New Times Pharmaceutical Co., Ltd.
Zitieren
APA
Zong, G., Li, J., Gong, X., Liu, Y., & Guo, X. (2024). Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04652-w
Vancouver
Zong G, Li J, Gong X, Liu Y, Guo X. Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04652-w
BibTeX
@article{Zong2024,
author = {Zong, Guangnan and Li, Jinlin and Gong, Xiushan and Liu, Yuanyuan and Guo, Xiuli},
title = {Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2024},
doi = {10.1007/s00280-024-04652-w}
}
EUVIMED